Skip to content

Haemonetics HAE Finite-Lived Intangible Assets, Accumulated Amortization

Finite-Lived Intangible Assets, Accumulated Amortization at other companies

Abbott logo
AbbottABT
TFX
TeleflexTFX
Boston Scientific logo
Boston ScientificBSX
Medtronic logo
MedtronicMDT
ICU Medical logo
ICU MedicalICUI
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.

The official record: Haemonetics’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's finite-lived intangible assets, accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's finite-lived intangible assets, accumulated amortization?
Haemonetics (HAE) reported finite-lived intangible assets, accumulated amortization of $352.12M in Q4 2025.
How has Haemonetics's finite-lived intangible assets, accumulated amortization changed year-over-year?
Haemonetics's finite-lived intangible assets, accumulated amortization increased by 13.0% year-over-year, from $311.6M to $352.12M.
What is the long-term trend for Haemonetics's finite-lived intangible assets, accumulated amortization?
Over 4 years (2021 to 2025), Haemonetics's finite-lived intangible assets, accumulated amortization has grown at a -0.3% compound annual growth rate (CAGR), from $320.64M to $316.31M.